|
|
|
|
|
|
|
|
Advanced Solid Tumours Clinical Trial: Phase I Study of AT13148, a Novel AGC Kinase Inhibitor [Conditions: Advanced Solid Tumours; Interventions: AT13148]
The purpose of this first clinical study of the noval
multiple AGC kinase inhibitor, AT13148, is to identify the recommended
dose for future studies in cancer patients by exploring the safety and
maximum tolerated dose and biological effects in patients with advanced
solid tumours...
Brief Summary
Official Title: “A Cancer
Research UK Phase I First in Man Study of the Novel AGC Kinase Inhibitor
AT13148 Given Orally in Patients With Advanced Solid Tumours.”
The purpose of this first clinical study of the noval multiple
AGC kinase inhibitor, AT13148, is to identify the recommended dose for
future studies in cancer patients by exploring the safety and maximum
tolerated dose and biological effects in patients with advanced solid
tumours.
- Study Type: Interventional
- Study Design: Masking: Open Label, Primary Purpose: Treatment
- Study Primary Completion Date: October 2015
Detailed Clinical Trial Description
AT13148 is a new drug which looks promising in laboratory
studies. We now wish to find out if it will be useful in treating
patients with cancer. AT13148 is a type of drug called a protein kinase
inhibitor. It blocks several different chemical messengers (enzymes)
called AGC kinase proteins. These chemical messengers are part of the
signaling process within cells which can make cells produce chemicals
that trigger and control cell growth and cell death. In some types of
cancer these chemical messengers are 'switched on' or 'switched off'
permanently due to changes in the genes of cells called "gene mutations"
leading to uncontrolled cancer cell growth. AT13148 targets multiple
protein kinases from three families of kinases unlike many of the other
protein kinase inhibitors currently being tested which target just one
or two kinases. This may mean that it will work better and in a wider
group of cancer patients. Patients will not be selected to take part
based on having these gene mutations for this first trial because we
want to learn more about which mutations are most important but this
would be the hope for future trials. The patient population anticipated
to benefit from this drug includes certain types of breast, prostate and
ovarian cancer which more commonly have these gene mutations.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.